
The study compared the innate immune effects of two FDA-approved anti-PD-L1 IgG1 mAbs—avelumab (native Fc) and durvalumab (mutated Fc). Using co-culture models, avelumab uniquely enhanced NK-cell function, dendritic cell (DC) maturation, and NK:DC crosstalk. Transcriptomic analysis revealed distinct gene expression and Fc-receptor-associated pathways activated by avelumab.
Like
Save
Share